China News Service, August 22 (Reporter Chen Jing) At the National Launch Conference of Taishengqi® Non-Small Cell Lung Cancer Combined Therapy Indications held in Shanghai on the 21st, a number of medical experts gave an in-depth interpretation of the global innovative drugs in China Reasons behind accelerated access.
In the past, it took a long time for foreign innovative drugs to enter the Chinese market. Some innovative drugs were officially introduced to China after many years of listing abroad, which to a certain extent affected the opportunities for domestic patients to receive international advanced drug treatments.
With the continuous deepening of the reform of China's drug review and approval system in recent years, the priority review and approval policy for "life-saving drugs" has been continuously improved and implemented, and the entire approval process has been greatly accelerated.
This makes the number of innovative drugs marketed in China, especially in the field of cancer treatment, continue to rise, further broadening the treatment options for cancer patients and families, and alleviating people's livelihood pain points.
Professor Lu Shun from the Chest Hospital of Shanghai Jiaotong University pointed out: “Behind the speed of China, it has witnessed the improvement of the clinical research level of the Chinese doctor team, which has helped Chinese data shine in the international academic community.” He said bluntly, especially in today’s rapid development. In the field of lung cancer immunotherapy, a team of clinical experts in China is working with the country to bring patients a variety of treatment plans that are synchronized with the world to maximize the clinical benefits of lung cancer patients.
It is understood that in recent years, with the steady improvement of the academic research ability and clinical level of Chinese clinicians, clinical trial data involving Chinese doctor teams have been more recognized by foreign countries.
Taking the global IMpower132 study in the field of lung cancer as an example, under the leadership of its principal investigator, Professor Lu Shun and his team, the Chinese cohort study successfully opened and included 163 local patients.
At the moment, the approval of innovative drugs is accelerating, which means that global new drugs will save time and costs when they are launched in China.
Professor Yang Jinji of Guangdong Provincial People's Hospital pointed out: "With more global clinical trials in China, more patients with major diseases such as malignant tumors will be expected to use advanced treatment drugs that are in line with international standards earlier and faster."
At the same time, Chinese clinicians diligently carry out many explorations to help China's overall clinical trial capabilities from "following" to "leading", and begin to exert an important influence in the field of international clinical research.
Professor Zhou Jianying of the First Affiliated Hospital of Zhejiang University School of Medicine mentioned: “More and more clinical and cohort data of Chinese patients have been adopted by global research. Conversely, it is also based on the advantages of Chinese patients’ data to provide innovative drugs in China. The review and approval provides an important and direct academic foundation, promotes the rapid patient access of global innovative drugs in China, and ultimately achieves the "Chinese speed" of new drug approval."
Lung cancer is one of the malignant tumors with the fastest increase in morbidity and mortality in China.
Professor Wang Baocheng from the 960th Hospital of the Chinese People’s Liberation Army introduced: “Non-small cell lung cancer (NSCLC) accounts for about 80% of lung cancer patients. About 75% of patients are in the middle and advanced stages when they are discovered. The 5-year survival rate is very low. The survival time and life of the patients The quality needs to be improved urgently." The treatment of lung cancer has made breakthroughs in the past 30 years, from traditional surgery, chemotherapy, radiotherapy, and targeted therapy to today's immunotherapy.
In the past ten years, immunotherapy is reshaping the pattern of lung cancer treatment, especially non-small cell lung cancer, which has a higher incidence, is undergoing tremendous changes in treatment methods.
Professor Cao Bangwei from Beijing Friendship Hospital affiliated to Capital Medical University said: “In recent years, Chinese clinical medical teams have aimed at lung cancer immunological drug research, actively explored new combined treatment strategies and diagnosis and treatment models, and constantly created'innovative solutions' for patients, so that they can have Increased treatment options and access to medicines.”
During the interview, the reporter learned that as the global research on lung cancer continues to deepen, a variety of combined treatment methods have become a trend now.
With the continuous innovation and breakthrough of immunotherapy, immunotherapy combined with chemotherapy has become one of the first-line standard treatments for non-small cell lung cancer, which can help patients survive for a long time and bring new hope for the treatment of these patients.
Professor Ge Di from Zhongshan Hospital of Fudan University believes: “The median progression-free survival benefit of the IMpower132 study in the Chinese cohort is even more obvious. The level of clinical treatment of lung cancer continues to improve, creating a new pattern for the diagnosis and treatment of non-small cell lung cancer in China, and benefiting more Chinese patients."
Professor Hu Jie from Zhongshan Hospital Affiliated to Fudan University emphasized: “The amazing data on Chinese patients in the IMpower132 study has provided strong support for the accelerated approval of innovative drugs, giving Chinese lung cancer patients the opportunity to benefit from new treatment options simultaneously with the world. More treatment options."
Chen Shaofeng, General Manager of China Oncology Division II of Roche Pharmaceuticals, said: “I believe that with continuous investment in the R&D pipeline and hand in hand with the Chinese clinician team, more and more lung cancer patients in China will learn from more innovative treatments. Benefit from the means." (End)